Objective-To determine whether doses of the pineal hormone melatonin alleviate jet lag.
Introduction
Jet lag is a common problem for air travellers after a flight through several time zones. It seems to be due to the time required to resynchronise the body's endogenous circadian rhythm to the night and day cycle of the new environment. Disturbed sleep, loss of mental efficiency, and tiredness during the day are commonly reported in the first week or so after a long haul flight.' These symptoms seem to increase with the number of time zones crossed,' and eastward ffights reportedly result in slower adaptation than westward flights. ' Recently there has been interest in the role of the pineal hormone melatonin in alleviating jet lag.4'5
Under normal circumstances melatonin is secreted at night in a 24 hour cycle. Some researchers have proposed that melatonin acts as a synchroniser for several other body rhythms.6 Thus taking melatonin at times when it should be released naturally might help adaptation to a distant time zone by hastening retraining ofthe body's endogenous circadian rhythms. In a double blind trial of melatonin in 17 subjects flying through eight time zones from San Francisco to London significantly fewer subjects taking melatonin reported jet lag.4 Biochemical data from this study showed that endogenous melatonin and cortisol rhythms resynchronised more rapidly in subjects taking melatonin.5 The study, however, was limited as jet lag was measured only once (retrospectively on day seven) and subjects travelled only in an easterly direction.
We investigated the effect of melatonin on jet lag after flights from Auckland to London and back. The study was designed so that feelings of jet lag and mood could be closely monitored over the 10 days after the flight, thus allowing closer examination of the readjustment.
Subjects and methods
Twenty volunteers with experience of transcontinental flights through at least five time zones were recruited from our associates, and all completed the study. Each gave informed consent to the study, which was approved by Waikato Hospital's ethics committee. The eight women and 12 men were aged 28 to 68. All subjects flew from Auckland to London in an eastward direction through 12 time zones on a 26 hour flight. They returned on a similar westward flight three weeks later. Subjects travelled in two groups one day apart in both directions.
Subjects were randomly assigned in a double blind procedure to receive melatonin or placebo on the outward flight and the other substance on the return journey. For three days before their flights they took 5 mg of melatonin (in gelatin lactose) or placebo (gelatin lactose) at between 1000 and 1200 local time. They also took a capsule at the same time during the ffight and at between 2200 and 2400 (destination time) for three days after their arrival.
On the day before the departure of both flights, on arrival, and at 1600 on days 1-5, 7, and 10 after arrival subjects completed visual analogue ratings of their feelings of jet lag and tiredness. They also completed a profile of moods states questionnaire designed to measure six fluctuating affective states,7 two of which were relevant to jet lag-namely, vigour-activity and fatigue-inertia. On these occasions they also recorded their hours of sleep over the past 24 hours. On the 10th day after arrival subjects completed a retrospective rating of jet lag on a six point scale ranging from "none at all" to "extreme." At this time subjects also answered questions on how many days it had taken for their sleep pattern and energy to return to normal and until they no longer felt tired during the day. Finally, subjects were asked to guess whether they had taken melatonin or placebo to control for their expectancy influencing rates. Identical procedures were followed on the return trip.
Data were analysed with the statistical package for the social sciences8 with one way analysis of variance and t tests. Figure 1 shows the visual analogue scores for jet lag reported on days 1-5, 7, and 10 after arrival. BrM.edj 1989;298:705-7 scores were consistently higher among those taking placebo for the first five days after arrival in both directions. Subjects taking melatonin reported significantly less overall jet lag at the retrospective rating on day 10 than did those taking placebo (mean (SD) score 2 15 (0 99) for melatonin, 3 40 (1 47) for placebo; F= 10-0, p<0 01). Figure 1 also shows that jet lag was more severe on the return journey; this was confirmed by the retrospective ratings, which were significantly higher after the return journey to New Zealand than the trip to London (t=2 14, df= 19, p<O0O5). The Figure   2 shows the pattern of responses on these two scales from the day of arrival to 10 days later. The scores for both groups showed a similar pattern to the visual analogue and retrospective ratings of jet lag with more vigour-activity and less fatigue-inertia among subjects taking melatonin for the first few days after arrival. In spite of differences in reported fatigue and vigour analysis of the reported hours of sleep each day showed essentially no difference between the groups from the day before departure to seven days after arrival.
Results
When subjects were asked to guess which group they were in (placebo or melatonin) nine subjects on the outward flight did not know, six incorrectly assigned themselves, and five correctly assigned themselves to the melatonin or placebo groups. On the return flight five subjects had no idea, six were incorrect, and nine correctly assigned themselves. This suggested that Auckland to London and back subjects' ideas of which drug they were taking were unlikely to have biased their response.
Subjects were asked to record any side effects experienced from taking the capsules. Twelve subjects reported no side effects when taking either placebo or melatonin. Two subjects taking melatonin reported a mild sedative effect lasting about a half an hour, and one other reported feeling more relaxed. Among subjects taking placebo one reported increased tiredness, one a greater feeling of relaxation, and one a greater depth of sleep.
Discussion
The results ofthis study support the use of melatonin as a remedy for jet lag on long haul flights. Subjects taking melatonin reported less jet lag and took less time to recover from their shift across 12 time zones. They also reported that they were less tired during the day and required less time to establish a normal sleeping pattern and reach their normal level of energy.
The effect of melatonin on jet lag may be due to its sedative properties.9 If this were so subjects taking melatonin would be expected to report longer periods of sleep than those taking placebo, though the effect might also be on the quality of sleep, which would be difficult to quantify. Our finding of no difference in hours of sleep between the groups suggests that melatonin may indeed operate by retraining the endogenous circadian rhythm.
The finding of greater jet lag after the return journey requires further investigation. Previous research on the difference in jet lag after westward and eastward flights has been based on the hypothesis that lengthening the natural circadian rhythm is easier than shortening it, and therefore eastward flights generally cause less disturbance than westward flights.' In our study, however, both eastward and westward flight times were across 12 time zones, and the difference in reported jet lag was not explained by the usual phase shifts required after shorter eastward and westward flights. The increased jet lag on the return westward flight may have been an artefact of the homeward journey with its return to a more demanding and less exciting environment for the subjects. This could be resolved by a similar study with subjects originating in two countries.
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ol E melatonin suggests that it is well tolerated at the dose used. The present study, however, does not indicate whether it is necessary to take melatonin before and during the flight or only after it. Further research is needed on the dose response characteristics of melatonin to optimise its effect in alleviating jet lag.
Overall the results support the use of melatonin for alleviating jet lag and tiredness after long haul flights and indicate further investigations necessary to maximise the positive effects of melatonin. Implicit in the nomenclature of cervical intraepithelial neoplasia is the concept of tumour progression and progressive loss of differentiation with increasing malignancy, which fits in well with the current understanding of the biology of carcinogenesis. It is presumed that at least some cases of cervical intraepithelial neoplasia grade I will eventually progress, probably through the higher grades of cervical intraepithelial neoplasia, to invasive carcinoma. Generally, cervical intraepithelial neoplasia grade I will probably take longer to progress to invasive carcinoma than a grade III lesion,2 but forecasting the probable rate of progression is impossible in individual cases. The size of the lesion is considered to be a more important prognostic indicator than its histological grading. Therefore, the Ninth Study Group of the Royal College of Obstetricians and Gynaecologists has recommended that all cervical intraepithelial neoplasia should be regarded as a continuum and that cervical intraepithelial neoplasia grade I should be treated as seriously as grade III lesions.' Hence the diagnosis of cervical intraepithelial neoplasia of any grade may have serious treatment implications for the patient.
This study was designed to test the ability of histopathologists to distinguish consistently between cervical intraepithelial neoplasia and the reactive proliferations of cervical squamous epithelium and to assess the variability of grading of cervical intraepithelial neoplasia among different histopathologists. A further study designed to test the degree of intraobserver variation is currently in progress.
Materials and methods
A total of 100 consecutive colposcopic biopsy specimens of the cervix-excluding those with a computer code indicating invasive carcinoma -that were received by the histopathology department at the University Hospital of Wales between 12 November
